Latest Fractyl Health News & Updates

See the latest news and media coverage for Fractyl. We track all announcements, press releases, and industry mentions in real time, all in one place.

Fractyl Health (Fractyl)

Developer of metabolic therapies for obesity and type 2 diabetes

fractyl.com

Headquarters: Burlington, United States
Founded year: 2010
Company type: Public company
Number of employees: 100–200

Last updated Today

Latest news about Fractyl Health (Fractyl)

In short: Fractyl Health advanced its metabolic pipeline, initiating human gene therapy trials and reporting positive weight maintenance data for Revita.

Company announcements

June 4 Fractyl

Fractyl reports positive one-year Revita weight maintenance results

Patients retained ~78% of GLP-1-induced weight loss after a single procedure; 33% continued losing weight.

May 11 Fractyl

Fractyl Health initiates first-in-human RJVA-001 trial

The Netherlands authorized a Phase 1/2 study of RJVA-001, the first AAV gene therapy for type 2 diabetes, with dosing and preliminary data expected in H2 2026.

April 27 Fractyl

Fractyl Health highlights REMAIN-1 trial results

Results show reduced weight regain after GLP-1 discontinuation using Revita®. Dr. Sullivan presents six-month data at DDW2026 on May 4th.

March 24 Fractyl

Fractyl Health reports Q4 and full year 2025 financial results

Announces completed REMAIN-1 randomization, new post-hoc analyses showing dose-dependent effects, FDA feedback, and cash runway into early 2027.

Media coverage

June 12 Yahoo Finance

Fractyl Health Inc (GUTS) Cleared for RJVA-001 Trial. Let's Look At Funding

Fractyl Health Inc (NASDAQ:GUTS) is one of billionaire Lee Ainslie's stocks with huge upside potential. The stock has gained roughly 18% over the past month...

June 4 Markets Insider

Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Participants retained ~78% of GLP-1 induced total body weight loss one year after discontinuation and a single Revita procedure 5.3% mean weight change observed with...

May 25 The Globe and Mail

Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category

Randomized 6-month data from the REMAIN-1 Midpoint Cohort expected in late January 2026 Topline 6-month data from the REMAIN-1 Pivotal Cohort and potential PMA submission...

May 16 Simply Wall St

Fractyl Health (GUTS) Is Up 14.0% After RJVA-001 Human Trial Nod And Q1 Profitability Shift – Has The Bull Case Changed? - Simply Wall St News

In May 2026, Fractyl Health reported first-quarter 2026 net income of US$9.22 million, reversing a prior-year loss, and secured authorization in the Netherlands to begin...

Never miss news about Fractyl

Track Fractyl and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Fractyl competitors & trending companies

Browse news for competitors to Fractyl and other trending companies.